| Scenario | Cost difference, $ | QALY difference | ICER |
|---|---|---|---|
| Base case (default values) | −7643 | 0.04 | Dominant |
| Only significant differences in comparative effectiveness included | −7423 | 0.02 | Dominant |
| Long-term time horizon (20 yr, public-payer perspective)‡ | 6110 | 0.92 | $6624 |
| Younger patient population (50 yr) | 7643 | 0.04 | Dominant |
| Patient population 70% female | −7643 | 0.04 | Dominant |
| No difference in asynchrony between PAV+ mode and PSV | −6658 | 0.03 | Dominant |
| PSV also has purchase cost ($13 500) | −7761 | 0.04 | Dominant |
| Per-day total hospital costs: intensive care unit $3592, general ward $113528 | −9408 | 0.04 | Dominant |
| Per-day direct hospital costs: intensive care unit $1732.90, general ward $499.7029 | −5832 | 0.04 | Dominant |
| Canadian efficacy data only15 | −8080 | 0.00 | Cost saving |
| Alternative RR for successful spontaneous breathing trial, OR 1.1647 | −7123 | 0.03 | Dominant |
| Alternative utility value assumed for mechanical ventilation, 0.2922 | −7643 | 0.03 | Dominant |
Note: ICER = incremental cost-effectiveness ratio, OR = odds ratio, PAV+ mode = proportional-assist ventilation with load-adjustable gain factors, PSV = pressure-support ventilation, QALY = quality-adjusted life year, RR = relative risk.
↵* Results are presented as PAV+ mode versus standard-care PSV, with difference in costs over difference in QALYs. The associated ICER is shown; in cases in which costs decrease and QALYs increase, the ICER is taken as dominant.
↵† Costs in 2017 Canadian dollars.
↵‡ Costs and quality of life utilities (measured with the EuroQoL EQ-5D instrument32) incurred after the first year are discounted at 1.5% per annum, in line with CAFTH guidelines.30 Annual utility decrements are also applied in the model after the first year.